| Serial Number | 79419666 |
| Word Mark | IOMX |
| Filing Date | Wednesday, December 18, 2024 |
| Status | 661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED |
| Status Date | Tuesday, January 27, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Chemical preparations for scientific and general industrial manufacturing purposes; Biochemical preparations, namely, genetically engineered polypeptides, for scientific purposes and proteins in raw material form for scientific and medical research, in particular antibodies and antibody-like polypeptides and proteins, and nucleic acid coding sequences for these for scientific purposes, in particular artificial polypeptides and proteins and nucleic acid coding sequences for these for scientific purposes; diagnostic preparations, except for medical or veterinary use. |
| Goods and Services | Pharmaceutical diagnostic medical and veterinary preparations; pharmaceutical preparations and formulations and medicinal health preparations for use in the treatment or prevention of diseases, ailments and/or disorders in humans and/or animals, in particular circulatory, respiratory, endocrine, neurological, cardiovascular, nutritional, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, ailments and/or disorders and the treatment or prevention of complications associated with such diseases, ailments and/or disorders; pharmaceutical preparations and formulations and medicinal health preparations for use in the treatment or prevention of illnesses, ailments and/or disorders in humans and/or animals, in particular bone, sensory organ, viral, urinary tract, kidney, metabolic or central nervous system diseases, complaints and/or disorders and the treatment or prevention of complications associated with such diseases, ailments and/or disorders; pharmaceutical preparations and formulations and medicinal health preparations for use in the treatment or prevention of diseases, ailments and/or disorders in humans and/or animals, in particular infectious, autoimmune or immunological, cell proliferative and/or oncological diseases, ailments and/or disorders, cancers, tumours and metastases and the treatment or prevention of complications associated with such diseases, ailments and/or disorders; pharmaceutical preparations and formulations and medical health preparations, in particular artificial polypeptides and proteins, in particular antibodies and antibody-like polypeptides and proteins, and nucleic acid coding for these, in particular for use in the following areas: treatment or prevention of various types of cancer, inflammatory diseases and autoimmune diseases; diagnostic preparations and biomarker reagents for medical or veterinary purposes; diagnostic preparations and diagnostic biomarker reagents for the diagnosis and/or prognosis of human and/or animal diseases, ailments and/or disorders, in particular circulatory, respiratory, endocrine, neurological, cardiovascular, nutritional, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, ailments and/or disorders and the diagnosis and/or prognosis in relation to complications associated with such diseases, ailments and/or disorders; diagnostic preparations and diagnostic biomarker reagents for medical purposes, namely, for the diagnosis and/or prognosis of human and/or animal diseases, ailments and/or disorders, in particular bone, sensory organ, virus, urinary tract, kidney, metabolic or central nervous system diseases, ailments and/or disorders and the diagnosis and/or prognosis in relation to complications associated with such diseases, ailments and/or disorders; diagnostic preparations and diagnostic biomarker reagents for medical purposes, namely, for the diagnosis and/or prognosis of diseases, ailments and/or disorders in humans and/or animals, in particular infectious, autoimmune or immunological, cell proliferative and/or oncological diseases, ailments and/or disorders, cancers, tumours and metastases and the diagnosis and/or prognosis in relation to complications associated with such diseases, ailments and/or disorders. |
| Goods and Services | Scientific services, namely, scientific research in the field of biology, chemistry or medicine, as well as immunology, oncology, molecular biology, cell biology, biochemistry and/or medicinal chemistry, and relating to the discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic agents and diagnostic biomarker reagents and/or diagnostic apparatus; conducting early evaluations in the field of new pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; development of platform technology, namely a cancer immunotherapy platform for the production of therapeutics; chemical, biological and biochemical laboratory services; conducting chemical, biochemical and biological analyses; Medical and scientific research in the field of cancer diagnostics for scientific purposes; Biological and biochemical laboratory; Forensic pathological biological and biochemical examination services; providing technical and scientific research information in the field of biotechnology about a biotechnology company, its technologies, projects, product-candidates, products and/or services via a web site on a global computer network; software design and development; design and development of computer software for use in the fields of biology, chemistry or medicine, in particular immunology, oncology, molecular biology, cellular biology, biochemistry and/or medicinal chemistry, as well as in the fields of discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic preparations and biomarker reagents and/or diagnostic apparatus. |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, March 20, 2025 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, March 20, 2025 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, March 20, 2025 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | iOmx Therapeutics AG |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | DE |
| Event Date | Event Description |
| Thursday, March 20, 2025 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, March 21, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, March 21, 2025 | APPLICATION FILING RECEIPT MAILED |
| Wednesday, June 4, 2025 | ASSIGNED TO EXAMINER |
| Friday, June 6, 2025 | NON-FINAL ACTION WRITTEN |
| Sunday, June 8, 2025 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Tuesday, July 29, 2025 | REFUSAL PROCESSED BY MPU |
| Tuesday, July 29, 2025 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Friday, August 15, 2025 | REFUSAL PROCESSED BY IB |
| Tuesday, January 27, 2026 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, January 27, 2026 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, January 27, 2026 | TEAS/EMAIL CORRESPONDENCE ENTERED |